Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

Summary: Background: Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and novel vaccines have been listed by the World Health Organization for emergency use. Additional alternative approaches may better address ongoing vaccination globally, where there remains an inequity i...

Full description

Bibliographic Details
Main Authors: Joon Young Song, Won Suk Choi, Jung Yeon Heo, Jin Soo Lee, Dong Sik Jung, Shin-Woo Kim, Kyung-Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Ji Yun Noh, Woo Joo Kim, François Roman, Maria Angeles Ceregido, Francesca Solmi, Agathe Philippot, Alexandra C. Walls, Lauren Carter, David Veesler, Neil P. King, Hun Kim, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Ho Keun Park, Hee Jin Cheong
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:EClinicalMedicine
Subjects:
SARS-CoV-2
COVID-19
Recombinant protein vaccine
Nanoparticle vaccine
Humoral immunity
Cellular immunity
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022002991

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022002991

Similar Items